RIPE-KG · Version 1.1.0 · Resource
ripekg:work/10.1016%2Fj.eururo.2013.04.001
https://w3id.org/ripe/ripe-kg/work/10.1016%2Fj.eururo.2013.04.001
| Subject | Predicate | Object |
|---|---|---|
ripekg:publication-details/RIPEA62FEC5B159F50CECOnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
ripe:concerns |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
ripekg:registry-evidence/RIPEA62FEC5B159F50CEC |
ripe:concerns |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
ripe:assesses |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
ripekg:study-design-evidence/RIPEA62FEC5B159F50CEC |
ripe:concerns |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
prism:doi |
10.1016/j.eururo.2013.04.001 |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
dcterms:creator |
ripekg:author/RIPEAU05FD8C4EC373DF0FCatherine Thompson |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
dcterms:creator |
ripekg:author/RIPEAU4066D09A3938410BVik Khullar |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
dcterms:creator |
ripekg:author/RIPEAU7B968040BB7F5104Christopher Nardo |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
dcterms:creator |
ripekg:author/RIPEAUB2F4506BAB0F4C38Jihao Zhou |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
dcterms:creator |
ripekg:author/RIPEAUC187CF85E394B14DKarl-Dietrich Sievert |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
dcterms:creator |
ripekg:author/RIPEAUD84F17CBF98E1D98Christopher Chapple |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
dcterms:creator |
ripekg:author/RIPEAUD89F1C08B4DBFBC5Cornelia Haag-Molkenteller |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
dcterms:creator |
ripekg:author/RIPEAUD9BB62DC899DE326Piotr Radziszewski |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
dcterms:creator |
ripekg:author/RIPEAUDC994F021B3369C6Scott Macdiarmid |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
dcterms:title |
OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW02D937929353463CImpact of urinary incontinence and overactive bladder on quality of life |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW04865F44EDD7F3D7An overview of treatment of overactive bladder syndrome in women |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW08D7905667437C17Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW118D44475FD7B3B2Reviewing the ICS 2002 terminology report: the ongoing debate |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW2F4EAF2DB393AAD4OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo-controlled trial |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW3E94A8F0CB0A644CCultural adaptation of a quality-of-life measure for urinary incontinence |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW475CD462A63A88D1Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW4D4BF0541CE5AABFOutcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW64D02D0402F9E9FAFunding/Support and role of the sponsor: Allergan, Inc. helped design and conduct the study; collect, manage, analyse, and interpret the data; and prepare, review, and approve the manuscript. Acknowledgement statement: The authors acknowledge Jennifer L. Giel, PhD, of Evidence Scientific Solutions |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW6BF9E370CAF14D34Impact of overactive bladder on work productivity in the United States: results from EpiLUTS |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW7E3A7E9E4652E567Prevalence and burden of overactive bladder in the United States |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW860A3BF2C9BB6C5CPersistence of antimuscarinic drug use |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW9473B9C373CC8492Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW9977D68DEF09AE98Urge incontinence: quality of life and patients' valuation of symptom reduction |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW9E644CAED91407B3Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEWA97622E48CDB7C35Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEWAC6536E2D9A88BDFImpact on quality of life of urinary incontinence and overactive bladder: a systematic literature review |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEWB12552E8FCFD689CThe standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEWB3BFB53DFD51E4D3Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEWB5F4BFC3D630EADCEfficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a doubleblind, placebo controlled, randomized, dose ranging trial |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEWBDFDB287B638EA47How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEWBF90FA6A9E88F48BAdministrative, technical, or material support: Nardo. Supervision: Nardo |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEWC312E16BA86688A7The total economic burden of overactive bladder in the United States: a disease-specific approach |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEWD12EFE04140539B1Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of Botox (onabotulinumtoxinA) and Dysport (abobotulinumtoxinA) |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEWD1C1D1744EC44A2FBotulinum toxin type A for the treatment of lower urinary tract disorders |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEWD2389EA7D9B63600The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEWD5D5B6B2487832D4The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEWD8B0B8157FEFF6DBOnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEWE6FB2B26B80B549EMeasurement of pyuria and its relation to bacteriuria |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEWE974A6C69E8D3912Utility scores for chronic conditions in a community-dwelling population |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEWEC91F50567E370EAincluding specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Christopher Chapple: consultant for AMS and Lilly; consultant and researcher for ONO; consultant, researcher, and speaker for Allergan |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEWEEFA85F0820EE110Christopher Chapple had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEWF197F199EC4A8891A new questionnaire to assess the quality of life of urinary incontinent women |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEWF2B9C34BFD7F2596How much is enough and who says so |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
rdf:type |
node1 |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
rdf:type |
http://purl.org/spar/fabio/Work |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
rdf:type |
rdfs:Resource |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
rdf:type |
owl:Thing |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
rdf:type |
prov:Entity |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
rdf:type |
ripe:WorkWork |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
owl:sameAs |
https://semopenalex.org/work/W2043938107 |